News and Press Releases
The Race For Answers: How Radboud University Medical Center Is Reducing The Time It Takes To Identify Rare Diseases
26 February 2024 – Nijmegen, the Netherlands – According to the United States’ National Institute of Health, an estimated 7,000 rare diseases collectively impact between 3.5% to 5.9% of the...
Category: Drug Discovery
Posted: February 27, 2024
University of Edinburgh acknowledges Pelago Patent and Use Of CETSA process
27 February 2024 – Stockholm, Sweden – Life Science Newswire – University of Edinburgh, UK, acknowledges Pelago Bioscience’s CETSA patent and use thereof in selected works in drug discovery research....
Category: Drug Discovery
Posted: February 27, 2024
Positive Results from Phase 3 Clinical Trial of Digital Therapeutic App SDT-001 and Submission for Marketing Approval in Japan
26 February 2024 -- Osaka, Japan -- Shionogi & Co announces the submission of a marketing approval application for the digital therapeutic app SDT-001, for commercialisation and sale in Japan,...
Category: Clinical Trials
Posted: February 27, 2024
Sequani invests in industry leading facilities as it eyes future growth
26 February 2024 -- Ledbury, UK -- As part of their strategic plans for growth and to meet the evolving needs of modern product developers, Ledbury-based contract research organisation (CRO)...
Category: Drug Discovery
Posted: February 27, 2024
SGD Pharma awarded 2024 gold EcoVadis rating in recognition of its commitment to sustainability
26 February 2024 -- Paris La Défense, France -- SGD Pharma, a global leader in glass pharmaceutical packaging, has achieved a gold medal in EcoVadis’ 2024 sustainability ratings. Building upon...
Category: Manufacturing and Packing
Posted: February 26, 2024
Janssen Receives Positive CHMP Opinion for CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for Treatment in Earlier Lines of Relapsed and Refractory Multiple Myeloma
Results from the phase 3 CARTITUDE-4 study, which supported the CHMP recommendation, showed that cilta-cel has the potential to offer significant benefit to patients in earlier lines of treatment Most...
Category: Clinical Trials
Posted: February 23, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
FGK Clinical Research GmbH Acquires Clinicology Ltd, Expanding Territorial Footprint in Europe
22 February 2024 -- Munich, Germany -- FGK Clinical Research GmbH, a European-based full-service provider of clinical research services, is thrilled to announce the successful acquisition of Clinicology Ltd, a...
Category: Clinical Trials
Posted: February 22, 2024
Aotearoa Clinical Trials Becomes First Site in New Zealand to Achieve both GCSA Certification and Silver Workforce Quality Accreditation
Certifications demonstrate Aotearoa Clinical Trials is working to the highest global best-practice standards, ratified by the industry 21 February 2024 -- Auckland, New Zealand and Maidenhead, UK -- Aotearoa Clinical Trials...
Category: Clinical Trials
Posted: February 21, 2024
Esme Green Building Middlemore Hospital 100 Hospital Rd Papatoetoe, 2025 Auckland, New Zealand
Kite Presents New Data for Yescarta (axicabtagene ciloleucel) CAR T-cell Therapy Highlighting Manufacturing Excellence and Cost-Effectiveness in the US
Data Highlights Industry-leading Manufacturing Success Rates for US Axicabtagene Ciloleucel Patients from Launch to Present Data Also Supports Cost-effectiveness of Axicabtagene Ciloleucel Versus Bispecific Antibodies 16 February 2024 – Stockley...
Category: BioManufacturing
Posted: February 21, 2024
Global End-to-End Solutions Partner to Life Sciences Organisations, AscellaHealth, joins Manchester Science Park
20 February 2024 -- Manchester, UK -- Global healthcare and specialty pharmacy solutions company providing innovative solutions to life sciences and biotech manufacturers, AscellaHealth, is expanding its UK presence with...
Category: Manufacturing and Packing
Posted: February 20, 2024
AscellaHealth, LLC 1055 Westlakes Drive Suite 175 Berwyn, PA 19312, US
Principal IRB Becomes Univo IRB With Support From QHP Capital
20 February 2024 -- North Carolina -- Today, Univo IRB was announced as the new company name for Principal IRB. Univo IRB is a next generation institutional review board (IRB) recently acquired...
Category: Clinical Trials
Posted: February 20, 2024
Biointelect and CR2O Forge New Strategic Partnership to Provide Advanced End-To-End Commercialisation Solutions for The Life Sciences Sector Globally
Driving more efficient and accelerated results from pre-clinical trials to commercialisation of new therapies for Australian, European and US firms 15 February 2024 -- Maarssen, The Netherlands, and Sydney, Australia...
Category: Other
Posted: February 15, 2024
Real-World Evidence Demonstrates Feasibility and Safety of Outpatient Administration of Yescarta (axicabtagene ciloleucel)
Findings show comparable safety for patients administered axicabtagene ciloleucel in the outpatient setting in the US to inpatient infusion Real-world evidence supports further exploration of use of outpatient administration of...
Category: Clinical Trials
Posted: February 15, 2024
Optibrium enables collaborative design in its StarDrop platform
The new Idea Tracker capability further improves the efficiency of drug discovery by supporting project management, idea sharing and molecule design tracking The software promotes collaboration within and across teams...
Category: Biotechnology, Drug Discovery
Posted: February 15, 2024
Optibrium Ltd. 7221 Cambridge Research Park, Beach Drive, Cambridge, CB25 9TL, UK
NICE has issued guidance for GSK’s Omjjara (momelotinib) as a treatment option for disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia
Myelofibrosis is a rare blood cancer that can result in the progressive scarring of bone marrow (fibrosis), impairing its normal function There are approximately 1,970 people living with myelofibrosis across...
Category: Clinical Trials
Posted: February 15, 2024
